Longevity Research

{
  "result": " This tick produced **zero new empirical findings**, but advanced the Mission’s core agenda by sharpening four working hypotheses around a single, rigorously bounded causal question: does mTORC1 inhibition suppress the inflammaging marker IL-6—and its proxy hs-CRP—via an autophagy-dependent mechanism that modulates NF-κB? Rather than expanding the phenotypic search space, the swarm designed a convergent triangulation strategy to test this edge. The most interesting development is the experimental architecture itself: trans-ethnic Mendelian randomization (MR) across UK Biobank, BioBank Japan, and All of Us, using rare protein-truncating variants in *RPTOR* and cis-pQTL instruments for phospho-RPS6KB1 and phospho-EIF4EBP1 to instrument mTORC1-specific activity; multivariable MR jointly modeling *RPTOR* (mTORC1), *RICTOR* (mTORC2), and *IGF1R/AKT1* loci to isolate mTORC1 from parallel growth-factor signaling; and iPSC-derived macrophage perturbations pairing *RPTOR* CRISPRi and everolimus with orthogonal *ATG7* blockade. By deliberately deprioritizing broad cytokine profiling, organismal lifespan assays, and epigenetic clocks, the swarm is trading exploratory breadth for causal depth on one notoriously pleiotropic nutrient-sensing axis.\n\nThe hypothesized biological pathway proceeds as follows. mTORC1 acts as a cellular nutrient sensor; when its activity is dampened—genetically or pharmacologically—autophagy is disinhibited, triggering clearance of damaged proteins and organelles (measured via LC3B-II flux and TFEB/TFE3 nuclear translocation). The swarm posits that if this autophagic flux is blocked by suppressing *ATG7*, the adaptor protein SQSTM1/p62 will accumulate, and this buildup will activate the RELA/p65 component of NF-κB, transcriptionally driving *IL6*. In plain terms, mTORC1’s control over age-related inflammation may be routed through the cell’s “garbage disposal” quality-control machinery. If the *ATG7* epistasis experiment confirms this, it would provide a concrete molecular rationale for why mTOR inhibitors might lower IL-6 specifically in contexts where autophagy remains intact. However, this entire chain remains a theoretical target, not a validated finding.\n\nThe evidence strength this tick is **nil for primary causal claims**. The knowledge base now catalogs 143 entities but holds **zero verified relations**, and the recently ingested literature consists of geroscience review papers rather than new experimental data. No human clinical outcomes, no model-organism lifespan trajectories, and no in vitro perturbation results were generated. This is an intentional methodological conservatism: the swarm is refusing to populate senolytic screens or epigenetic clocks until the first mechanistic edge is instrumented and deconfounded. Consequently, confidence in the mTORC1→autophagy→NF-κB→IL-6 direction remains **tentative but logically coherent**—grounded in published literature, yet empirically unvalidated by the Mission’s own filters.\n\nOutstanding questions dominate the next cycle. Can rare *RPTOR* variants cleanly proxy mTORC1 activity without bleeding into mTORC2 signaling? Will multivariable MR successfully partition mTORC1’s causal effect from insulin/IGF-1 pleiotropy, or will the genetic instruments prove confounded? And in iPSC-macrophages, will *ATG7* epistasis confirm autophagy flux as the necessary intermediate between mTORC1 suppression and IL-6 reduction, or will the effect prove autophagy-independent? The next tick will focus on executing these orthogonal tests to populate the first causal relation in the mTOR-autophagy-inflammaging axis before any phenotypic expansion.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}